Description
Product Usage Information
Western Blotting: 1:1000
Simple Western™: 1:10 - 1:50
IHC Leica Bond: 1:200 - 1:800
Immunohistochemistry (Paraffin): 1:50 - 1:200
Immunofluorescence (Frozen): 1:50 - 1:200
Immunofluorescence (Immunocytochemistry): 1:50 - 1:200
Flow Cytometry (Fixed/Permeabilized): 1:50
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 89872 .
Protocol
Available protocols: Western Blotting, IHC Leica Bond, Immunohistochemistry (Paraffin), Immunofluorescence (Frozen), Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized)
Specificity / Sensitivity
Arginase-1 (D4E3M™) Rabbit Monoclonal Antibody recognizes endogenous levels of total arginase-1 protein. This antibody does not cross-react with arginase-2.
Species Reactivity: Human, Mouse, Rat
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val47 of human arginase-1 protein.
Background
L-arginine plays a critical role in regulating the immune system (1-3). In inflammation, cancer, and certain other pathological conditions, myeloid cell differentiation is inhibited leading to a heterogeneous population of immature myeloid cells, known as myeloid-derived suppressor cells (MDSCs). MDSCs are recruited to sites of cancer-associated inflammation and express high levels of arginase-1 (4). Arginase-1 catalyzes the final step of the urea cycle converting L-arginine to L-ornithine and urea (5). Thus, MDSCs increase the catabolism of L-arginine resulting in L-arginine depletion in the inflammatory microenvironment of cancer (4,6). The reduced availability of L-arginine suppresses T cell proliferation and function and thus contributes to tumor progression (4,6). Arginase-1 is of great interest to researchers looking for a therapeutic target to inhibit the function of MDSCs in the context of cancer immunotherapy (7). In addition, research studies have demonstrated that arginase-1 distinguishes primary hepatocellular carcinoma (HCC) from metastatic tumors in the liver, indicating its value as a potential biomarker in the diagnosis of HCC (8,9).
Alternate Names
ARG1; ARGI1; arginase 1; Arginase-1; arginase, liver; Liver-type arginase; Type I arginase
